Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Omnicell (OMCL) is a leading health information services business based in the US. It opened the day at $152.43 after a previous close of $151.5. During the day the price has varied from a low of $150.03 to a high of $153.13. The latest price was $151.24 (25 minute delay). Omnicell is listed on the NASDAQ and employs 3,800 staff. All prices are listed in US Dollars.
Finder's Pick for
Beginners
Finder's Pick for
Free Trades
Finder's Pick for
Commodity Stocks
Finder's Pick for
US Stocks
| Open | $152.43 |
|---|---|
| High | $153.13 |
| Low | $150.03 |
| Close | $151.24 |
| Previous close | $151.50 |
| Change | $-0.26 |
| Change % | -0.1716% |
| Volume | 195,046 |
| 52-week range | $104.32 - $187.29 |
|---|---|
| 50-day moving average | $125.26 |
| 200-day moving average | $152.28 |
| Wall St. target price | $167.44 |
| PE ratio | 70.9946 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $1.49 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $151.24 from 2022-05-13
| 1 week (2022-05-06) | 31.05% |
|---|---|
| 1 month (2022-04-12) | N/A |
| 3 months (2022-02-16) | 13.01% |
| 6 months (2021-11-16) | -15.95% |
| 1 year (2021-05-14) | 14.65% |
|---|---|
| 2 years (2020-05-15) | 141.48% |
| 3 years (2019-05-16) | 86.30% |
| 5 years (2017-05-16) | 270.69% |
Valuing Omnicell stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Omnicell's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Omnicell's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 71x. In other words, Omnicell shares trade at around 71x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Omnicell's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.28. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Omnicell's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Omnicell's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $137.6 million.
The EBITDA is a measure of a Omnicell's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.2 billion |
|---|---|
| Operating margin TTM | 7.3% |
| Gross profit TTM | $555 million |
| Return on assets TTM | 2.73% |
| Return on equity TTM | 6.9% |
| Profit margin | 6% |
| Book value | $24.29 |
| Market capitalisation | $4.7 billion |
TTM: trailing 12 months
We're not expecting Omnicell to pay a dividend over the next 12 months.
Over the last 12 months, Omnicell's shares have ranged in value from as little as $104.32 up to $187.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Omnicell's is 1.1534. This would suggest that Omnicell's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Omnicell, Inc. , together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc.
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.
Read more…
Using our proprietary algorithm, we’ve found the best blue chip stocks on the TSX, NYSE and Nasdaq based on price, performance and more.
Read more…
Want to invest in satellite companies? We’ve put together a list of 6 satellite stocks you should keep your eye on.
Read more…Everything we know about the Hanover Bancorp, Inc. IPO, plus information on how to buy in.
Everything we know about the PrimeBlock IPO, plus information on how to buy in.
Everything we know about the Actelis Networks IPO, plus information on how to buy in.
Everything we know about the ProFrac Holding Corp IPO, plus information on how to buy in.
Everything we know about the Wytec International IPO, plus information on how to buy in.
Here are some of the best stocks for inflation periods to reduce the negative impacts of inflation on your portfolio.
Choose from many account and investment types to invest in global markets, but expect to pay high commissions with HSBC InvestDirect, which doesn’t have an app.
Our Flahmingo review tells you how to buy fractional shares of some of your favourite US companies with as little as $1.
Steps to owning and managing EXPD stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing PRU stock, with 24-hour and historical pricing before you buy.
